This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BioPharm America
September 13–14, 2023 | Raleigh Convention Center, North Carolina
September 19–20, 2023 | Digital Partnering

Amaro Therapeutics, Inc.


Company Description or Summary

Amaro is a preclinical, platform company focused on the emerging field of extra-oral bitter taste receptors (TAS2R) as therapeutic targets. The therapeutic potential of TAS2R modulation has been suggested in a broad range of human conditions from longevity to immuno-metabolic disorders to modulation of the microbiome. Via acquisition, the company is capitalizing on ten years of preclinical and clinical experience in the development of disease modifying compounds targeting these GPCR receptors.